Skip to main content

Table 2 Comparison of clinical parameters, HRpQCT, and BMD among AS patients based on sex, mSASSS, and HLA-B27

From: Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis

Variable Total Sex mSASSS HLA-B27
(N = 53) Men Women mSASSS >0 mSASSS = 0 HLA-B27(+) HLA-B27(−)
(n = 29) (n = 24) (n = 28) (n = 25) (n = 36) (n = 16)
Men (%) 29 (55) 20 (71) 9 (36)* 22 (61) 6 (38)
Caucasians 40 (75) 20 (69) 20 (83) 20 (71) 20 (80) 30 (83) 10 (63)
Age (years) 44 ± 12 45 ± 12 43 ± 11 48 ± 11* 39 ± 11 45 ± 12 40 ± 11
Disease duration (years) 17 (7–27) 21 (9–28)* 12 (4–20) 24 (9–32)* 12 (4–20) 20 (8–28) 11 (6–22)
BMI (kg/m2) 27 (22–32) 27 (25–32) 24 (21–32) 27 (24–30) 26 (22–32) 26 (22–29) 23 (27–36)
Current smoking (%) 20 (38) 13 (44) 7 (29) 12 (43) 8 (32) 14 (39) 5 (31)
Heavy alcohol use (%)a 2 (4) 2 (7) 0 (0) 1 (4) 1 (4) 1 (3) 1 (6)
Corticosteroid use (%) 3 (6) 1 (3) 2 (8) 0 (0) 2 (8) 0 (0) 2 (13)
Bisphosphonate use (%) 4 (9) 3 (16) 1 (5.3) 2 (7) 2 (8) 2 (5) 2 (11)
Use of DMARDs (%) 7 (13) 5 (17) 2 (8) 5 (18) 2 (8) 3 (8) 3 (19)
NSAID use (%) 47 (89) 26 (90) 21 (88) 25 (89) 22 (88) 29 (81) 10 (63)
IBD (%) 8 (18) 3 (10) 5 (13) 3 (10) 5 (20) 4 (11) 3 (19)
Psoriasis (%) 8 (18) 5 (17) 3 (13) 6 (20) 2 (8) 6 (17) 2 (13)
BASDAI 6.7 (4.8–7.9) 5.8 (4.3–7.0)* 7.5 (5.7–8.4) 6.5 (4.3–7.5) 6.8 (5.5–8.0) 6.6 (4.3–7.5) 7.5 (4.7–8.8)
mSASSS 2 (0–11) 8 (1–16)* 0 (0–2) 2 (0–15) 1 (0–7)
mSASSS > 0 (%) 28 (53) 20 (69)* 8 (33) 21 (58) 6 (38)
Fragility fractures (%) 5 (9) 4 (14) 1 (4) 4 (14) 1 (4) 4 (11) 2 (13)
Serum ESR (mm/hour) 21.9 ± 22.5 18 ± 19 25 ± 25 30.7 ± 26.9* 12.8 ± 10.9 21 ± 23 22 ± 20
Serum CRP (mg/l) 13.3 ± 16.7 13 ± 17 11 ± 15 19.6 ± 20.1* 6.1 ± 6.8 13 ± 18 12 ± 13
SAP (IU) 94 ± 41 88 ± 19 103 ± 60 106.8 ± 46.6* 80.7 ± 30.1 92 ± 41 99 ± 42
  1. Data expressed as mean ± standard deviation, median (interquartile range) or number (% N) unless specified otherwise
  2. aHeavy alcohol use: >14 drinks per week
  3. *p <0.05, men vs. women
  4. **p <0.05, high mSASSS vs. normal mSASSS
  5. p <0.05, HLA-B27(+) vs. HLA-B27(−)
  6. AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMD bone mineral density, BMI body mass index, CRP C-reactive protein, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, HRpQCT high-resolution peripheral quantitative computerized tomography, IBD Inflammatory bowel disease, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NSAID nonsteroidal antiinflammatory drug, SAP Serum alkaline phosphatase
\